Prognostic factors in non-small cell lung cancer: A decade of progress

Chest

Volumn 122, Issue 3, 2002, Pages 1037-1057

  Brundage, Michael D ^a   Davies, Diane ^a   Mackillop, William J ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Carcinoma; Multivariate analysis; Non small cell lung cancer; Prognosis

Indexed keywords

ADVANCED CANCER; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DATA BASE; ENVIRONMENT; HOST; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MEDLINE; MULTIVARIATE ANALYSIS; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STATISTICAL ANALYSIS;

EID: 0036384579     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.122.3.1037     Document Type: Review

References (290)

1. Ginsberg RJ, Vokes EE, Raben A. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott-Raven, 1999; 849-950
2. Mackillop WJ, Zhou Y, Dixon P, et al. Variation in the management and outcome of non-small cell lung cancer in Ontario. Radiother Oncol 1994; 32:106-115
3. Feinstein AR. Clinical biostatistics XIV: the purposes of prognostic stratification. Clin Pharmacol Ther 1972; 13:285-297
4. Brundage MD, Feldman-Stewart D, Cosby R, et al. Phase I study of a decision aid for patients with locally advanced non-small cell lung cancer. J Clin Oncol 2001; 19:1326-1335
5. Mackillop WJ. The importance of prognosis in cancer medicine. In: Gospodarowicz MK, Henson DE, Hutter RBP, et al, eds. Prognostic factors in cancer. New York, NY: Wiley & Sons, 2001
6. Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J 1994; 7:1350-1364
7. Feld R, Borges M, Giner V, et al. Prognostic factors in non-small cell lung cancer. Lung Cancer 1994; 11(suppl):S19-S23
8. Smit EF, Groen HJ, Splinter TA, et al. New prognostic factors in resectable non-small cell lung cancer. Thorax 1996; 51:638-646
9. Mountain CF. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest 1995; 108:246-254
10. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
11. Stewart LA, Pignon JP. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909
12. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9:1618-1626
13. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univar-iate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients: the European Lung Cancer Working Party. J Clin Oncol 1995; 13:1221-1230
14. Hespanhol V, Queiroga H, Magalhaes A, et al. Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995; 13:253-267
15. Takigawa N, Segawa Y, Okahara M, et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 1996; 15:67-77
16. Ganz PA, Lee JJ, Siau J. Quality of life assessment: an independent prognostic variable for survival in lung cancer. Cancer 1991; 67:3131-3135
17. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997; 33:1025-1030
18. Herndon JE, Fleishman S, Kornblith AB, et al. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 1999; 85:333-340
19. Montazeri A, Milroy R, Hole D, et al. Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 2001; 31:233-240
20. Langendijk H, Aaronson NK, de Jong JM, et al. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 2000; 55:19-25
21. Emami B, Perez CA. Lung. In: Perez CA, ed. Radiation oncology. Philadelphia, PA: Lippincott, 1993
22. Anderson TM, Moy PM, Holmes EC. Factors affecting survival in superior sulcus tumors. J Clin Oncol 1986; 4:1598-1603
23. Beyer DC, Weisenburger T. Superior sulcus tumors. Am J Clin Oncol 1986; 9:156-161
24. Detterbeck FC. Pancoast (superior sulcus) tumors. Ann Thorac Surg 1997; 63:1810-1818
25. Shaw RR. Pancoast's tumor. Ann Thorac Surg 1984; 37:343-345
26. Sabiston DCJ, Spencer FC. Surgery of the chest. Philadel-phia, PA: WB Saunders, 1995
27. Feinstein AR, Wells CK. A clinical-severity staging system for patients with lung cancer. Medicine (Baltimore) 1990; 69:1-33
28. Wigren T, Oksanen H, Kellokumpu-Lehtinen P. A practical prognostic index for inoperable non-small-cell lung cancer. J Cancer Res Clin Oncol 1997; 123:259-266
29. Choi N, Baumann M, Flentjie M, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 2001; 31:43-56
30. Mori M, Kohli A, Baker SP, et al. Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer: are they useful? Mod Pathol 1997; 10:572-577
31. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89:881-886
32. Clayton F. The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu 1988; 23:361-394
33. Perkins P, Kemp BL, Putnam JBJ, et al. Pretreatment characteristics of carcinoid tumors of the lung which predict aggressive behavior. Am J Clin Oncol 1997; 20:285-288
34. Kayser K, Kayser C, Rahn W, et al. Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically. J Surg Oncol 1996; 63:99-106
35. D'Amico TA, Massey M, Herndon JE, et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. Thorac Cardiovasc Surg 1999; 117:736-743
36. Johnson BE. Biologic and molecular prognostic factors: impact on treatment of patients with non-small cell lung cancer. Chest 1995; 107:287S-290S
37. Goto I, Yoneda S, Yamamoto M, et al. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996; 56:3725-3730
38. Watine J. Further comments on "A practical prognostic index for inoperable non-small-cell lung cancer": a clinical biologist's point of view. J Cancer Res Clin Oncol 1998; 124:581-583
39. Jacobson DR. ras mutations in lung cancer. In: Brambilla C, Brambilla E, eds. Lung tumors: fundamental biology and clinical management. New York, NY: Marcel Dekker, 1999
40. Michalides RJ. Deregulation of the cell cycle in lung cancer. In: Brambilla C, Brambilla E, eds. Lung tumors: fundamental biology and clinical management. New York, NY: Marcel Dekker, 1999
41. Huncharek M, Kupelnick B, Geschwind JF, et al. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett 2000; 153:219-226
42. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000; 6:4055-4063
43. Choma D, Daures JP, Quantin X, et al. Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data. Br J Cancer 2001; 85:14-22
44. van Rens MT, de la Riviere AB, Elbers HR, et al. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117:374-379
45. Saito Y, Yamakawa Y, Kiriyama M, et al. Evaluation of new TNM lung cancer classification. Jpn Thorac Cardiovasc Surg 2000; 48:499-505
46. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70:1102-1110
47. Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest 2000; 117:1247-1255
48. Jassem J, Skokowski J, Dziadziuszko R, et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. Thorac Cardiovasc Surg 2000; 119:1141-1146
49. Davidson JR, Brundage MD, Feldman-Stewart D. Lung cancer treatment decisions: patients' desires for participation and information. Psychooncology 1999; 8:511-520
50. Brundage MD, Davidson JR, Mackillop W, et al. Using a treatment-tradeoff methods to elicit preferences for the treatment of locally advanced non-small cell lung cancer. Med Decis Making 1998; 18:256-267
51. Buccheri G, Ferrigno D. Prognostic value of the tissue polypeptide antigen in lung cancer. Chest 1992; 101:1287-1292
52. Palomares MR, Sayre JW, Shekar KC, et al. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 1996; 78:2119-2126
53. Thorogood J, Bulman AS, Collins T, et al. The use of discriminant analysis to guide palliative treatment for lung cancer patients. Clin Oncol (R Coll Radiol) 1992; 4:22-26
54. Takai E, Yano T, Iguchi H, et al. Tumor-induced hypercalcemia and parathyroid hormone-related protein in lung carcinoma. Cancer 1996; 78:1384-1387
55. Buccheri G, Ferrigno D, Tamburini M Karnofsky, and ECOG. performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A:1135-1141
56. Bonomi P, Gale M, Rowland K, et al. Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment. Int J Radiat Oncol Biol Phys 1991; 20:247-252
57. Sugiura S, Ando Y, Minami H, et al. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997; 3:47-50
58. Komaki R, Pajak TF, Byhardt RW, et al. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433. Lung Cancer 1993; 10:189-197
59. Ando M, Ando Y, Sugiura S, et al. Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res 1999; 90:249-253
60. Wigren T. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer. Radiother Oncol 1997; 44:9-15
61. Kreisman H, Lisbona A, Olson L, et al. Effect of radiologic stage III substage on nonsurgical therapy of non-small cell lung cancer. Cancer 1993; 72:1588-1596
62. Thomas M, Rube C, Semik M, et al. Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu. Eur Respir J 1999; 13:424-429
63. Naito T, Satoh H, Ishikawa H, et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 1997; 17:4743-4746
64. Hilsenbeck SG, Raub WAJ, Sridhar KS. Prognostic factors in lung cancer based on multivariate analysis. Am J Clin Oncol 1993; 16:301-309
65. Buccheri G, Ferrigno D, Ginardi C, et al. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 1997; 33:50-55
66. Jacoulet P, Depierre A, Moro D, et al. Long-term survivors of small-cell lung cancer (SCLC): a French multicenter study; Groupe d'Oncologie de Langue Francaise. Ann Oncol 1997; 8:1009-1014
67. Taguchi O, Gabazza EC, Yasui H, et al. Prognostic significance of plasma D-dimer levels in patients with lung cancer. Thorax 1997; 52:563-565
68. Wojtukiewicz MZ, Zacharski LR, Moritz TE, et al. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul Fibrinolysis 1992; 3:429-437
69. Pedersen LM, Milman N. Prevalence and prognostic significance of proteinuria in patients with lung cancer. Acta Oncol 1996; 35:691-695
70. Buccheri G. Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur Respir J 1998; 11:173-178
71. Miyamoto H, Harada M, Isobe H, et al. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 1991; 51:6346-6350
72. Pence JC, Kerns BJ, Dodge RK, et al. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 1993; 128:1382-1390
73. Pifarre A, Rosell R, Monzo M, et al. Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer. Br J Cancer 1997; 75:184-189
74. Kawasaki M, Nakanishi Y, Kuwano K, et al. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res 1997; 3:1195-1200
75. Volm M, Drings P, Wodrich W. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol 1993; 119:507-510
76. Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung Cancer 1993; 10:21-33
77. Carles J, Rosell R, Ariza A, et al. Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993; 10:209-219
78. Diez M, Torres A, Ortega L, et al. Value of serum neuron-specific enolase in nonsmall cell lung cancer. Oncology (Huntingt) 1993; 50:127-131
79. Takekawa H, Takaoka K, Tsukamoto E, et al. Thallium-201 single photon emission computed tomography as an indicator of prognosis for patients with lung carcinoma. Cancer 1997; 80:198-203
80. Bulzebruck H, Drings P, Kayser K, et al. Classification of lung cancer: first experiences with the new TNM classification (4th edition). Eur Respir J 1991; 4:1197-1206
81. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111:1718-1723
82. Lima C, Matsui K, Kitagawa M, et al. Analysis of prognostic factors in patients with resected peripheral T1 adenocarcinoma of the lung. Pathol Res Pract 1993; 189:1149-1153
83. Shimizu J, Watanabe Y, Oda M, et al. Results of surgical treatment of stage I lung cancer. Nippon Geka Gakkai Zasshi 1993; 94:505-510
84. Harpole DHJ, Herndon JE, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55:51-56
85. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. Thorac Cardiovasc Surg 1995; 109:120-129
86. Sagawa M, Sakurada A, Fujimura S, et al. Five-year survivors with resected pN2 nonsmall cell lung carcinoma. Cancer 1999; 85:864-868
87. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases: Leuven Lung Cancer Group. Ann Thorac Surg 1997; 63:1441-1450
88. Lacasse Y, Bucher HC, Wong E, et al. "Incomplete resection" in non-small cell lung cancer: need for a new definition; Canadian Lung Oncology Group. Ann Thorac Surg 1998; 65:220-226
89. Chandrachud LM, Pendleton N, Chisholm DM, et al. Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer 1997; 76:1367-1375
90. Jefferson MF, Pendleton N, Faragher EB, et al. "Tumour volume" as a predictor of survival after resection of non-small-cell lung cancer (NSCLC). Br J Cancer 1996; 74:456-459
91. Bourke W, Milstein D, Giura R, et al. Lung cancer in young adults. Chest 1992; 102:1723-1729
92. Massard G, Moog R, Wihlm JM, et al. Bronchogenic cancer in the elderly: operative risk and long-term prognosis. Thorac Cardiovasc Surg 1996; 44:40-45
93. Conill C, Astudillo J, Verger E. Prognostic significance of metastases to mediastinal lymph node levels in resected non-small cell lung carcinoma. Cancer 1993; 72:1199-1202
94. Kondo H, Asamura H, Suemasu K, et al. Prognostic significance of pleural lavage cytology immediately after thoracotomy in patients with lung cancer. Thorac Cardiovasc Surg 1993; 106:1092-1097
95. Buhr J, Berghauser KH, Gonner S, et al. The prognostic significance of tumor cell detection in intraoperative pleural lavage and lung tissue cultures for patients with lung cancer. Thorac Cardiovasc Surg 1997; 113:683-690
96. Fukuse T, Hirata T, Tanaka F, et al. Prognosis of ipsilateral intrapulmonary metastases in resected nonsmall cell lung cancer. Eur J Cardiothorac Surg 1997; 12:218-223
97. Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? A multivariate prognostic factor analysis of 151 patients. Thorac Cardiovasc Surg 1993; 106:90-94
98. Sobue T, Suzuki T, Fujimoto I, et al. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habit. Jpn J Cancer Res 1991; 82:33-39
99. Wertzel H, Siebert H, Lange W, et al. Results after surgery in stage-I bronchogenic carcinoma. Thorac Cardiovasc Surg 1998; 46:365-369
100. Diez M, Torres A, Maestro ML, et al. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer. Br J Cancer 1996; 73:1248-1254
101. Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer: a report from the Lung Cancer Study Group. Cancer 1984; 54:1802-1813
102. Muller T, Marshall RJ, Cooper EH, et al. The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis. Eur J Cancer Clin Oncol 1985; 21:1461-1466
103. Clee MD, Hockings NF, Johnston RN. Bronchial carcinoma: factors influencing postoperative survival. Br J Dis Chest 1984; 78:225-235
104. Macchiarini P, Fontanini G, Hardin MJ, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. Thorac Cardiovasc Surg 1993; 106:80-89
105. Brechot JM, Chevret S, Charpentier MC, et al. Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma: correlation with TNM stage and disease free and overall survival. Cancer 1996; 78:2111-2118
106. Kessler R, Gasser B, Massard G, et al. Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer. Ann Thorac Surg 1996; 62:1489-1493
107. Komaki R, Milas L, Ro JY, et al. Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1998; 40:787-796
108. Komaki R, Fujii T, Perkins P, et al. Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1996; 36:601-605
109. Duarte IG, Bufkin BL, Pennington MF, et al. Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. Thorac Cardiovasc Surg 1998; 115:652-658
110. Lucchi M, Fontanini G, Mussi A, et al. Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 1997; 12:535-541
111. Nestle U, Nieder C, Abel U, et al. A palliative accelerated irradiation regimen (PAIR) for advanced non-small-cell lung cancer (NSCLC). Radiother Oncol 1996; 38:195-203
112. Fontanini G, Vignati S, Bigini D, et al. Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin Cancer Res 1996; 2:1067-1075
113. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998; 4:241-249
114. Fontanini G, Vignati S, Lucchi M, et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br J Cancer 1997; 75:1295-1301
115. Takanami I, Tanaka F, Hashizume T, et al. Tumor angiogenesis in pulmonary adenocarcinomas: relationship with basic fibroblast growth factor, its receptor, and survival. Neoplasma 1997; 44:295-298
116. Lee TK, Horner RD, Silverman JF, et al. Morphometric and morphologic evaluations in stage III non-small cell lung cancers: prognostic significance of quantitative assessment of infiltrating lymphoid cells. Cancer 1989; 63:309-316
117. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A: a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med 1991; 324:1084-1090
118. Miyake M, Taki T, Hitomi S, et al. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. N Engl J Med 1992; 327:14-18
119. Tanaka F, Miyahara R, Ohtake Y, et al. Lewis Y antigen expression and postoperative survival in non-small cell lung cancer. Ann Thorac Surg 1998; 66:1745-1750
120. Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 1998; 157:1093-1097
121. Jorgensen LG, Hirsch FR, Skov BG, et al. Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. Br J Cancer 1991; 63:151-153
122. Abratt RP. Combined modality therapy of lung cancer and lung tolerance. J Clin Oncol 1996; 14:1402-1403
123. Laberge F, Fritsche HA, Umsawasdi T, et al. Use of carcinoembryonic antigen in small cell lung cancer: prognostic value and relation to the clinical course 1. Cancer 1987; 59:2047-2052
124. Sculier JP, Feld R, Evans WK, et al. Carcinoembryonic antigen: a useful prognostic marker in small-cell lung cancer. J Clin Oncol 1985; 3:1349-1354
125. Carey FA, Prasad US, Walker WS, et al. Prognostic significance of tumor deoxyribonucleic acid content in surgically resected small-cell carcinoma of lung. Thorac Cardiovasc Surg 1992; 103:1214-1217
126. Ichinose Y, Hara N, Ohta M, et al. Postoperative adjuvant chemotherapy in non-small cell lung cancer: prognostic value of DNA ploidy and post-recurrent survival. J Surg Oncol 1991; 46:15-20
127. Zimmerman PV, Hawson GA, Bint MH, et al. Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet 1987; 2:530-533
128. Salvati F, Teodori L, Gagliardi L, et al. DNA flow cytometric studies of 66 human lung tumors analyzed before treatment: prognostic implications. Chest 1989; 96:1092-1098
129. Dazzi H, Thatcher N, Hasleton PS, et al. DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir Med 1990; 84:217-223
130. Rice TW, Bauer TW, Gephardt GN, et al. Prognostic significance of flow cytometry in non-small-cell lung cancer. Thorac Cardiovasc Surg 1993; 106:210-217
131. Ten Velde GP, Schutte B, Vermeulen A, et al. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur J Cancer Clin Oncol 1988; 24:455-460
132. Cibas ES, Melamed MR, Zaman MB, et al. The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung. Cancer 1989; 63:1552-1556
133. Carp NZ, Ellison DD, Brophy PF, et al. DNA content in correlation with postsurgical stage in non-small cell lung cancer. Ann Thorac Surg 1992; 53:680-683
134. Ojala A, Kallioniemi OP, Wigren T, et al. Flow cytometric analysis of tumour DNA profile related to response to radiotherapy and survival in inoperable lung cancer. Acta Oncol 1990; 29:983-988
135. Volm M, Drings P, Mattern J, et al. Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer 1985; 56:1396-1403
136. Schmidt RA, Rusch VW, Piantadosi S. A flow cytometric study of non-small cell lung cancer classified as T1N0. Cancer 1992; 69:78-85
137. Muguerza JM, Diez M, Torres AJ, et al. Prognostic value of flow cytometric DNA analysis in non-small-cell lung cancer: rationale of sequential processing of frozen and paraffin-embedded tissue. World J Surg 1997; 21:323-329
138. Kolodziejski L, Niezabitowski A, Gasinska A. Clinical and flow cytometric prognostic factors in surgically treated squamous cell lung cancer. Lung Cancer 1997; 16:173-182
139. Volm M, Mattern J, Muller T, et al. Flow cytometry of epidermoid lung carcinomas: relationship of ploidy and cell cycle phases to survival; a five-year follow up study. Anticancer Res 1988; 8:105-112
140. Volm M, Hahn EW, Mattern J, et al. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 1988; 48:2923-2928
141. van Bodegom PC, Baak JP, Stroet-van Galen C, et al. The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage 1 resected squamous cell lung cancer and long-term follow up. Cancer 1989; 63:143-147
142. Scagliotti GV, Micela M, Gubetta L, et al. Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer 1993; 29A:363-365
143. Pujol JL, Simony J, Jolimoy G, et al. Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer 1996; 74:964-970
144. Ishida T, Kaneko S, Akazawa K, et al. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 1993; 53:5000-5003
145. Fujii M, Motoi M, Saeki H, et al. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer. Acta Med Okayama 1993; 47: 103-108
146. Bellotti M, Elsner B, Paez DL, et al. Neural networks as a prognostic tool for patients with non-small cell carcinoma of the lung. Mod Pathol 1997; 10:1221-1227
147. Rodrigues OR, Antonangelo L, Yagi N, et al. Prognostic significance of argyrophilic nucleolar organizer region (Ag-NOR) in resected non-small cell lung cancer (NSCLC). Jpn J Clin Oncol 1997; 27:298-304
148. Bernardi FD, Antonangelo L, Beyruti R, et al. A prognostic model of survival in surgically resected squamous cell carcinoma of the lung using clinical, pathologic, and biologic markers. Mod Pathol 1997; 10:992-1000
149. Antonangelo L, Bernardi FD, Capelozzi VL, et al. Morphometric evaluation of argyrophilic nucleolar organizer region is useful in predicting long-term survival in squamous cell carcinoma of the lung. Chest 1997; 111:110-114
150. Alama A, Costantini M, Repetto L, et al. Thymidine labelling index as prognostic factor in resected non-small cell lung cancer. Eur J Cancer 1990; 26:622-625
151. Silvestrini R, Muscolino G, Costa A, et al. Could cell kinetics be a predictor of prognosis in non-small cell lung cancer? Lung Cancer 1991; 7:165-170
152. Patel MS, Thigpen JT, Vance RB, et al. Basal cell carcinoma with lung metastasis diagnosed by fine-needle aspiration biopsy. South Med J 1999; 92:321-324
153. Hirata T, Fukuse T, Naiki H, et al. Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res 1998; 58:1108-1110
154. Pantel K, Passlick B, Vogt J, et al. Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J Clin Oncol 1998; 16:1407-1413
155. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323:561-565
156. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52:2665s-2669s
157. Mitsudomi T, Steinberg SM, Oie HK, et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991; 51:4999-5002
158. Harada M, Dosaka-Akita H, Miyamoto H, et al. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992; 69:72-77
159. Selby P. The value of quality of life scores in clinical cancer research. Eur J Cancer 1993; 29A:1656-1657
160. Nemunaitis J, Klemow S, Tong A, et al. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. Am J Clin Oncol 1998; 21:155-160
161. Huang CL, Taki T, Adachi M, et al. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer. Int J Oncol 1998; 12:553-563
162. Cho JY, Kim JH, Lee YH, et al. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer 1997; 79:462-467
163. Sugio K, Ishida T, Yokoyama H, et al. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992; 52:2903-2906
164. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993; 53:1-4
165. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52:4828-4831
166. Morkve O, Halvorsen OJ, Skjaerven R, et al. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res 1993; 13:571-578
167. Mitsudomi T, Oyama T, Kusano T, et al. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993; 85: 2018-2023
168. Huang C, Taki T, Adachi M, et al. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer. Oncogene 1998; 16:2469-2477
169. Vega FJ, Iniesta P, Caldes T, et al. p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. Br J Cancer 1997; 76:44-51
170. Nishio M, Koshikawa T, Kuroishi T, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996; 14:497-502
171. Dalquen P, Moch H, Feichter G, et al. DNA aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Arch 1997; 431: 173-179
172. Dosaka-Akita H, Hu SX, Fujino M, et al. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer 1997; 79:1329-1337
173. Komiya T, Hosono Y, Hirashima T, et al. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 1997; 3:1831-1835
174. Higashiyama M, Doi O, Kodama K, et al. bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol 1997; 64:48-54
175. Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 1997; 15:2456-2466
176. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998; 77:663-669
177. Ebert W, Muley T, Drings P. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res 1996; 16:2161-2168
178. Bohm J, Koch S, Gais P, et al. Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J Pathol 1996; 178: 402-409
179. Pujol JL, Grenier J, Parrat E, et al. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 1996; 154:725-733
180. Pujol JL, Parrat E, Lehmann M, et al. Lung cancer chemotherapy: response-survival relationship depends on the method of chest tumor response evaluation. Am J Respir Crit Care Med 1996; 153:243-249
181. Niklinski J, Burzykowski T, Niklinska W, et al. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. Eur Respir J 1998; 12:1424-1428
182. Hirashima T, Takada M, Komiya T, et al. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 1998; 18:4713- 4716
183. Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell
184. Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of CYFRA 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997; 33:385-391
185. Adachi M, Taki T, Konishi T, et al. Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol 1998; 16: 1397-1406
186. Higashiyama M, Doi O, Kodama K, et al. Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 1997; 74:205-211
187. Adachi M, Taki T, Ieki Y, et al. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996; 56:1751-1755
188. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68:162-165
189. Tateishi M, Ishida T, Mitsudomi T, et al. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 1991; 27:1372-1375
190. Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50:5184-5187
191. Takanami I, Tanana F, Hashizume T, et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology (Huntingt) 1996; 53:392-397
192. Siegfried JM, Weissfeld LA, Singh-Kaw P, et al. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997; 57:433-439
193. Fontanini G, Vignati S, Boldrini L, et al. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 1997; 3:861-865
194. Kibbelaar RE, Moolenaar KE, Michalides RJ, et al. Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. Eur J Cancer 1991; 27:431-435
195. Tisi E, Lissoni P, Angeli M, et al. Postoperative increase in soluble interleukin-2 receptor serum levels as predictor for early recurrence in non-small cell lung carcinoma. Cancer 1992; 69:2458-2462
196. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 1997; 3:1051-1058
197. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996; 73:294-300
198. Caputi M, De Luca L, Papaccio G, et al. Prognostic role of cyclin D1 in non small cell lung cancer: an immunohistochemical analysis. Eur J Histochem 1997; 41:133-138
199. Higashiyama M, Doi O, Kodama K, et al. Influence of cathepsin D expression in lung adenocarcinoma on prognosis: possible importance of its expression in tumor cells and stromal cells, and its intracellular polarization in tumor cells. J Surg Oncol 1997; 65:10-19
200. Ten Velde GP, Havenith MG, Volovics A, et al. Prognostic significance of basement membrane deposition in operable squamous cell carcinomas of the lung. Cancer 1991; 67: 3001-3005
201. Pena CM, Rice TW, Ahmad M, et al. Significance of perioperative blood transfusions in patients undergoing resection of stage I and II non-small-cell lung cancers. Chest 1992; 102:84-88
202. van Klaveren RJ, Festen J, Otten HJ, et al. Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg 1993; 56:300-304
203. Kawai T, Suzuki M, Kase K, et al. Expression of carbohydrate antigens in human pulmonary adenocarcinoma. Cancer 1993; 72:1581-1587
204. Fujino M, Dosaka-Akita H, Harada M, et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 1995; 76:2457-2463
205. Pappot H, Francis D, Brunner N, et al. p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis. Clin Cancer Res 1996; 2:155-160
206. Mitsudomi T, Oyama T, Nishida K, et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res 1996; 2:1185-1189
207. Dalquen P, Sauter G, Torhorst J, et al. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 1996; 178:53-58
208. Takanami I, Imamuma T, Hashizume T, et al. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol 1996; 61:205-208
209. Takanami I, Tanaka F, Hashizume T, et al. Transforming growth factor-beta isoforms expressions in pulmonary adenocarcinomas as prognostic markers: an immunohistological study of one hundred and twenty patients. Oncology (Huntingt) 1997; 54:122-128
210. Aberg T. Selection mechanisms as major determinants of survival after pulmonary metastasectomy. Ann Thorac Surg 1997; 63:611-612
211. Graziano SL, Tatum AH, Gonchoroff NJ, et al. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer. Clin Cancer Res 1997; 3:87-93
212. Fujisawa T, Yamaguchi Y. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung. Cancer 1997; 79:474-481
213. Komiya T, Hirashima T, Takada M, et al. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 1997; 17:3721-3724
214. Adachi M, Taki T, Huang C, et al. Reduced integrin alpha3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung. J Clin Oncol 1998; 16:1060-1067
215. Tanaka F, Kawano Y, Li M, et al. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol 1999; 17:2728-2736
216. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol 1999; 17:3201-3206
217. Suzuki K, Nagai K, Yoshida J, et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma: a comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 1999; 86:1976-1984
218. Taga S, Osaki T, Ohgami A, et al. Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg 1999; 230:715-720
219. Lee JH, Machtay M, Kaiser LR, et al. Non-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. Radiology 1999; 213: 845-852
220. Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999; 91:2032-2038
221. Hashimoto T, Tokuchi Y, Hayashi M, et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 1999; 59:5572-5577
222. Hommura F, Dosaka-Akita H, Kinoshita I, et al. Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer 1999; 81:696-701
223. Werle B, Lotterle H, Schanzenbacher U, et al. Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients. Br J Cancer 1999; 81:510-519
224. Groeger AM, Caputi M, Esposito V, et al. Independent prognostic role of p16 expression in lung cancer. Thorac Cardiovasc Surg 1999; 118:529-535
225. Sawyer TE, Bonner JA, Gould PM, et al. Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials. Int J Radiat Oncol Biol Phys 1999; 45:315-321
226. Okada M, Tsubota N, Yoshimura M, et al. Evaluation of TMN classification for lung carcinoma with ipsilateral intrapulmonary metastasis. Ann Thorac Surg 1999; 68:326-330
227. Kubuschok B, Passlick B, Izbicki JR, et al. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 1999; 17:19-24
228. Foa P, Fornier M, Miceli R, et al. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers 1999; 14:92-98
229. Tomizawa Y, Adachi J, Kohno T, et al. Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma. Clin Cancer Res 1999; 5:1139-1146
230. Yoshino I, Nakanishi R, Osaki T, et al. Unfavorable prognosis of patients with stage II non-small cell lung cancer associated with macroscopic nodal metastases. Chest 1999; 116:144-149
231. Suzuki K, Nagai K, Yoshida J, et al. The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. Thorac Cardiovasc Surg 1999; 118:145-153
232. Tanaka F, Yanagihara K, Ohtake Y, et al. p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. Jpn J Cancer Res 1999; 90:432-438
233. Lavezzi AM, Santambrogio L, Bellaviti N, et al. Prognostic significance of different biomarkers in non-small cell lung cancer. Oncol Rep 1999; 6:819-825
234. Fu XL, Zhu XZ, Shi DR, et al. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 1999; 23:143-152
235. Miyake M, Adachi M, Huang C, et al. A novel molecular staging protocol for non-small cell lung cancer. Oncogene 1999; 18:2397-2404
236. Tsumatori G, Ozeki Y, Takagi K, et al. Relation between the serum E-selectin level and the survival rate of patients with resected non-small cell lung cancers. Jpn J Cancer Res 1999; 90:301-307
237. Laudanski J, Chyczewski L, Niklinska WE, et al. Expression of bcl-2 protein in non-small cell lung cancer: correlation with clinicopathology and patient survival. Neoplasma 1999; 46:25-30
238. Koomagi R, Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999; 84:239-243
239. Puglisi F, Barbone F, Damante G, et al. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Mod Pathol 1999; 12:318-324
240. Suzuki K, Nagai K, Yoshida J, et al. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg 1999; 67:927-932
241. Marchetti A, Bertacca G, Buttitta F, et al. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res 1999; 5:2077-2081
242. Nisman B, Amir G, Lafair J, et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999; 19:3549-3552
243. Fujisawa T, Iizasa T, Saitoh Y, et al. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 1999; 17:2086-2091
244. Foa P, Fornier M, Miceli R, et al. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res 1999; 19:3613-3618
245. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. 'Invading edge vs. inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol 2000; 192:140-149
246. Hirashima T, Komiya T, Nitta T, et al. Prognostic significance of telomeric repeat length alterations in pathological stage I-IIIA non-small cell lung cancer. Anticancer Res 2000; 20:2181-2187
247. Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 2000; 20:1527-1533
248. Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161:589-594
249. Cagini L, Monacelli M, Giustozzi G, et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000; 74:53-60
250. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7:603-607
251. Oyama T, Osaki T, Nose N, et al. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Anticancer Res 2000; 20:505-510
252. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000; 82:1427-1432
253. Huang CI, Taki T, Higashiyama M, et al. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Br J Cancer 2000; 82:374-380
254. Boldrini L, Calcinai A, Samaritani E, et al. Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 2000; 83:480-486
255. Schneider PM, Praeuer HW, Stoeltzing O, et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000; 83:473-479
256. Fukuse T, Hirata T, Naiki H, et al. Prognostic significance of proliferative activity in pN2 non-small-cell lung carcinomas and their mediastinal lymph node metastases. Ann Surg 2000; 232:112-118
257. Cantero R, Torres AJ, Maestro ML, et al. Prognostic value of the quantified expression of p185 in non-small cell lung cancer. Thorac Cardiovasc Surg 2000; 119:1119-1125
258. Mishina T, Dosaka-Akita H, Hommura F, et al. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 2000; 6:11-16
259. Moldvay J, Scheid P, Wild P, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 2000; 6:1125-1134
260. Skaug V, Ryberg D, Kure EH, et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000; 6:1031-1037
261. Yano T, Tanikawa S, Fujie T, et al. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 2000; 36:601-609
262. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000; 18:2981-2989
263. Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000; 6:4789-4796
264. Reinmuth N, Brandt B, Kunze WP, et al. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 2000; 16:991-996
265. Varela G, Novoa N, Jimenez MF. Influence of age and predicted forced expiratory volume in 1 s on prognosis following complete resection for non-small cell lung carcinoma. Eur J Cardiothorac Surg 2000; 18:2-6
266. Niklinska W, Burzykowski T, Chyczewski L, et al. p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland. Eur J Cancer Prev 2000; 9:81-87
267. Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000; 6:3944-3948
268. Ohta Y, Nozawa H, Tanaka Y, et al. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. Thorac Cardiovasc Surg 2000; 119:804-813
269. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000; 6:4073-4081
270. Blaes F, Klotz M, Huwer H, et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thorac Surg 2000; 69:254-258
271. Jazieh AR, Hussain M, Howington JA, et al. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer. Ann Thorac Surg 2000; 70:1168-1171
272. Prommegger R, Widner B, Murr C, et al. Neopterin: a prognostic variable in operations for lung cancer. Ann Thorac Surg 2000; 70:1861-1864
273. Shiba M, Kohno H, Kakizawa K, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer 2000; 89:1457-1465
274. Ko JL, Cheng YW, Chang SL, et al. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer. Int J Cancer 2000; 89:265-270
275. Yuan A, Yu CJ, Chen WJ, et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 2000; 89:475-483
276. Tang X, Khuri FR, Lee JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000; 92:1511-1516
277. Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 2000; 162:1957-1963
278. Tanaka F, Otake Y, Nakagawa T, et al. Prognostic significance of polysialic acid expression in resected non-small cell lung cancer. Cancer Res 2001; 61:1666-1670
279. Muller-Tidow C, Metzger R, Kugler K, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001; 61:647-653
280. Pelletier MP, Edwardes MD, Michel RP, et al. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 2001; 44:180-188
281. Cox G, Jones JL, Andi A, et al. A biological staging model for operable non-small cell lung cancer. Thorax 2001; 56:561-566
282. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001; 19:432-441
283. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 2001; 19:448-457
284. Vassilakopoulos T, Troupis T, Sotiropoulou C, et al. Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. Lung Cancer 2001; 32:137-144
285. Puglisi F, Aprile G, Bruckbauer M, et al. Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Lett 2001; 162:97-103
286. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001; 8:72-79
287. Kara M, Ohta Y, Tanaka Y, et al. Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer. Ann Thorac Surg 2001; 71:944-948
288. Manac'h D, Riquet M, Medioni J, et al. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. Ann Thorac Surg 2001; 71:1088-1093
289. Izumi M, Nakanishi Y, Yoshino I, et al. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 2001; 92:446-451
290. Offersen BV, Pfeiffer P, Hamilton-Dutoit S, et al. Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer 2001; 91:1500-1509